Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.14+0.09 (+1.28%)
At close: 04:00PM EDT
7.12 -0.02 (-0.28%)
After hours: 07:57PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.47B
Enterprise value 1.96B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.95
Price/book (mrq)56.59
Enterprise value/revenue 5.53
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.88
52-week change 3-2.99%
S&P500 52-week change 320.87%
52-week high 37.95
52-week low 34.03
50-day moving average 36.39
200-day moving average 35.72

Share statistics

Avg vol (3-month) 33.64M
Avg vol (10-day) 32.95M
Shares outstanding 5206.38M
Implied shares outstanding 6206.38M
Float 8191.22M
% held by insiders 11.16%
% held by institutions 189.81%
Shares short (28 Jun 2024) 417.88M
Short ratio (28 Jun 2024) 44.83
Short % of float (28 Jun 2024) 48.74%
Short % of shares outstanding (28 Jun 2024) 48.66%
Shares short (prior month 31 May 2024) 436.18M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -58.69%
Operating margin (ttm)-15.62%

Management effectiveness

Return on assets (ttm)-10.85%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)355.4M
Revenue per share (ttm)1.81
Quarterly revenue growth (yoy)34.90%
Gross profit (ttm)N/A
EBITDA -82.09M
Net income avi to common (ttm)-208.58M
Diluted EPS (ttm)-1.07
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)336.55M
Total cash per share (mrq)1.63
Total debt (mrq)852.9M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.73
Book value per share (mrq)-2.31

Cash flow statement

Operating cash flow (ttm)-101.31M
Levered free cash flow (ttm)-72.42M